Efficacy and safety of tafolecimab a new PCSK9 inhibitor in patients with hyperlipidemia: a systematic review and meta-analysis of randomized controlled trials

Efficacy and safety of tafolecimab a new PCSK9 inhibitor in patients with hyperlipidemia: a systematic review and meta-analysis of randomized controlled trials

Abstract Background Hyperlipidemia is a common condition as nearly over 50% of adult Americans have high low-density lipoprotein (LDL) levels. Hyperlipidemia increases the risk of strokes, myocardial infarction, and other vascular events. PCSK9 monoclonal antibodies are one of the available options...

Full description

Saved in:
Bibliographic Details
Main Authors: Ali Ashraf Salah Ahmed, Ahmad Alkheder, Mohamed Ahmed Ali, Mohamed R. Abdelraouf, Toka Ahmed Ashour, Hazem Mohamed Salamah, Abdelrahman Mahmoud, Diaa Hakim
Format: Article
Language:English
Published: SpringerOpen 2025-06-01
Series:The Egyptian Heart Journal
Subjects:
Hyperlipidemia
Tafolecimab
Hypercholesterolemia
Hyperlipoproteinemia
Atherosclerosis
Online Access:https://doi.org/10.1186/s43044-025-00653-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s43044-025-00653-z

Similar Items